Prostate Cancer

Boswellia has one of its strongest treatment-resistance stories in prostate cancer, especially in docetaxel-resistant disease models.

Overview

The key theme here is resistance reversal through suppression of Akt and STAT3 survival signalling.

Key preclinical data

• AKBA suppresses docetaxel-resistant prostate cancer in vitro and in vivo

• Reduces phospho-Akt and phospho-STAT3 in resistant tumours

• Shows activity in androgen-sensitive and androgen-independent models

• Orthotopic prostate cancer work supports genuine in vivo tumour suppression

Clinical positioning

This is still preclinical, but clinically meaningful because docetaxel resistance is a major unmet need.

References

AKBA suppresses docetaxel-resistant prostate cancer cells in vitro and in vivo by blocking Akt and STAT3 signaling
https://pmc.ncbi.nlm.nih.gov/articles/PMC6786291/

Jump to another Boswellia page

Core pages

• Boswellia in Oncology Overview

• Evidence Summary

• Anticancer Mechanisms

• Boswellia Evidence by Cancer Type

Mechanism deep dives

• Redox Dual Action

• NRF2 Impact

• Ferroptosis Findings

• Immune Effects

Practical pages

• Pharmacokinetics & Metabolism

• Safety & Interactions

• Synergistic Combinations

• Hydroxychloroquine + Boswellia

• Dosing & Timing

• Sourcing Quality Boswellia

Cancer-type pages

• Glioblastoma & Brain Tumours

• Breast Cancer

• Colorectal Cancer

• Pancreatic Cancer

• Prostate Cancer

• Non-Small Cell Lung Cancer

• Ovarian Cancer

• Other Cancer Types